IMMP
Immutep Ltd
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Immutep has 7 disclosed suppliers and 1 disclosed customer in SEC filings.
—
—
—
SentenceIn June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase III trial in non-small cell lung cancer called TACTI-004. In addition to working together, MSD was also supplying KEYTRUDA at no cost for the trial.
SentenceGrant income is earned by the Company from governments primarily in Australia and France related to Australian Research and Development Rebates and France's Crédit d'Impôt Recherche and is recognized at fair value when there is reasonable assurance that the grant will be received and the Company will comply with all attached conditions.
IMMP 20-Faccession 0001193125-26-429413
SentenceGrant income is earned by the Company from governments primarily in Australia and France related to Australian Research and Development Rebates and France's Crédit d'Impôt Recherche and is recognized at fair value when there is reasonable assurance that the grant will be received and the Company will comply with all attached conditions.
IMMP 20-Faccession 0001193125-26-429413
SentenceIn November 2022, Immutep signed a new Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to conduct the INSIGHT-005 trial. It is the second agreement entered into by Immutep with Merck KGaA and Pfizer
IMMP 20-Faccession 0001193125-25-249346
SentenceWe retained PricewaterhouseCoopers as our independent registered public accounting firm.
IMMP 20-Faccession 0001193125-26-429413
SentenceThe Company received US$ 20 million (A$ 28.8 million) as an upfront license fee from Dr Reddy's in January 2026, of which US$ 2.7 million (A$ 4.1 million) was recognized as revenue and US$ 17.3 million (A$ 25.8 million) as unearned revenue in the Company's Half-Year Report at December 31, 2025.
Expected move
No implied move.
Immutep Ltd
2.99